University of Texas System

Baker Hughes, a Ge Compnay, LLC

Baker Hughes Corporation

Emory University

University of Michigan

Arizona Board of Regents on Behalf of the University of Arizona

Health Research, Inc.

Bj Services, LLC

Jia Zhou

Hong Sun

Qi Qu

Leiming Li

Chunyong Ding

Scott Gregory Nelson

Zhiqing Liu

Qiang Shen

Haijun Chen

Pingyuan Wang

Xiaolan Wang

Xingming Deng

Magnus Legemah

Jimin Xu

Allan R Brasier

Pei-Yong Shi

Xuping Xie

Michael Guerin

Xiaodong Cheng

Fang Mei

Csaba Szabo

Bing Tian

Haitao Hu

Fernanda Laezza

John A Allen

Daniel E Felsing

Na Ye

Mark Hellmich

D V Satyanarayana Gupta

Harold Dean Brannon

Dong Shen

Paul S Carman

Brian Benedict Beall

Harold Gene Hudson

Nouri Neamati

Frances H DeBenedictis

Ahmed M Gomaa

Thomas Ray Starks, Ii

Kathryn A Cunningham

Tom N Royce

Zhong Li

Sanjiv Sur

John F Hancock

Dharini Van Der Hoeven

Hongmin Li

Xiuzhen Fan

Erik Rytting

Tamara Tsalkova

Kenneth M Johnson

Cheng Z Wang

Syed Ali

Qing-Yu Zhang

Jin Mo Chung

Jun-Ho La

Oluwarotimi Folorunso

Yuting Kuang

Aditya Singh

Jeffrey A Frost

Haiying Chen

Frances Debenedictis

Embodiments are directed to novel GPR52 activators. In particular, a series of novel 1-(pyrimidin-4-yl)indoline-4-carboxamide analogs that have been identified as potent and selective GPR52 agonists. The optimized GPR52 agonist that, for example, can be used as a valuable pharmacological tool or a drug candidate for investigating the physiological and therapeutic potential of GPR52 activation for various human diseases.

Heterocyclic g-protein-coupled receptor 52 (GPR52) agonists

The present invention relates to novel small molecules Formula I and pharmaceutically acceptable salts thereof as well as the preparation and the use thereof to inhibit FGF13-1b.

Non-opioid anti-pain medication

A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2′,5(3H)-dione analogues, the use thereof and the preparation thereof.

Substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2',5(3H)-dione analogues

The invention relates generally to the following novel fendiline derivatives, and the preparation and use thereof: Formula I (I) and Formula II (II)

Fendiline derivatives

The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of inhibiting viral replication including contacting one or more cells that have been infected with a virus with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the virus comprises a flavivirus. Also disclosed is a method of treating and/or preventing a flavivirus infection and/or a condition resulting from a flavivirus infection including administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof under conditions effective to treat and/or prevent a flavivirus infection and/or a condition resulting from a flavivirus infection.

Compounds and methods for inhibiting viral replication and methods of treating and preventing flaviviral infections

A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2&#x2032;,5(3H)-dione analogues, the use thereof and the preparation thereof.

Substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2&#x2032;,5(3H)-dione analogues

Certain embodiments are directed to methods of using BRD4 inhibitors for treating IgE-mediated diseases.

BRD4 inhibitor treatment of IgE-mediated diseases

Embodiments are directed to a series of novel EPAC antagonists that are designed, synthesized and evaluated in an effort to develop diversified analogues based on the scaffold of the previously identified high-throughput (HTS) hit ESI-09.

EPAC antagonists

Certain embodiments are directed to small molecule selective inhibitors of the BRD4 bromodomain. Compounds described herein can be used to modulate the bronchiolar NFkB-BRD4 axis, which plays a role in acute neutrophilic response to viral molecular patterns. Compounds described herein can be developed as preventive and therapeutic agents for various human diseases and conditions.

Inhibitors of bromodomain-containing protein 4 (BRD4)

The invention relates generally to novel small molecule BRD4 modulators for HIV, the preparation thereof as well as the use thereof.

Small molecule BRD4 modulators for HIV epigenetic regulation

The present invention relates to novel small molecule modulators of Nav1.6 channels of the general formulae (I), (II), (III) and (IV), and the uses thereof. 

Fine-tune modulators of neuronal excitability for neuropsychiatric disorders

The invention relates generally to novel EPAC1 activators, such as Formula I and the preparation thereof as well as the use of EPAC1 activators as human immunodeficiency virus (HIV) latency reversal agents (LRAs). 

EPAC1 activators as HIV latency reversal agents (LRA)

A method of fracturing a subterranean formation penetrated by a well comprises: forming a fracturing composition comprising a carrier fluid; and a superabsorbent polymer component comprising one or more of the following: a first composite of a proppant and a first superabsorbent polymer in an unhydrated form, the first superabsorbent polymer being at least partially embedded in a void area of the proppant; a coated superabsorbent polymer; a superabsorbent material having a three-dimensional network; or a second composite of a second superabsorbent polymer and a slow-release breaker; and pumping the hydraulic fracturing composition into the subterranean formation to create or enlarge a fracture.

Fracturing fluids and methods of treating hydrocarbon formations

This invention is in the field of medicinal chemistry. In particular, the invention relates to novel small molecule compounds having a quinolin-8-yl-nicotinamide structure (e.g., a compound having Formula I: which are useful in treating, ameliorating, or preventing various forms of cancer (e.g., pancreatic cancer).

Substituted amides for treating and preventing cancer

Growing community of inventors

League City, TX, United States of America

Jia Zhou